Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
Zepbound (for obesity) and Mounjaro (for type 2 diabetes)
Several randomized controlled trials demonstrated improved cardiovascular outcomes in type 2 diabetics taking GLP-1RAs [2024]
3 Supportive secondary end points were not included in the statistical testing hierarchy and, as such, not controlled for multiplicity
People often describe less hunger, fewer cravings, and less fixation on food, which makes healthy choices feel more realistic to maintain
A more recent meta-analysis including studies published up to 2023 showed that the aforementioned metabolic benefits of combination therapy do not likely exceed those of GLP-1 receptor agonists alone [7]
:max_bytes(150000):strip_icc()/26Q1_WL_oral-sema_newsroom_1920x1008-1dfa18327b724266bed50c36ab0b9d49.jpg)
